IL2 and melanoma: These promising results led to multicenter phase II trials with the intralesional application of L19-IL-2 as single agent or in combination with L19-TNF-α in stage IIIB/IIIC and IVM1 melanoma patients as recently reviewed by Weide et al. (64).